Mikrobiomik is a biopharmaceutical start-up born to research and develop drugs based on the human microbiome, providing innovative solutions in serious chronic diseases, currently without a therapeutic alternative.

From the company, and in words of its CEO, Juan Basterra, “we aspire to lead the paradigm shift that will involve designing therapeutic solutions based on the human microbiome and being the first global company to market the first drug based on faecal microbiota in the EU”.

Intestinal microbiota transplants, a solution for dysbiosis

The decrease in microbial diversity or a predominance of some species over others, causes what is known as intestinal dysbiosis, a focus for proliferation of harmful bacteria, triggers of a multitude of diseases.

The transfer of intestinal microbiota consists of transferring lyophilized faecal microbiota from a healthy donor to the intestinal tract of a diseased receptor, in order to restore balance, thus eliminating dysbiosis.This transfer is carried out from a treatment consisting of administration of 4 capsules.

New generation of drugs

The added value of the therapeutic treatment that Mikrobiomik proposes through the capsules, supposes the elimination of the procedural risks of more invasive methods that have been used to date to achieve this transfer. Therefore, Mikrobiomik aspires to become the first global company to market, at European level, the first biological medicine for the treatment of some serious chronic diseases.

Supporting innovation

Seed Capital Bizkaia, through Fund I, participates in this innovative project. Fund I is one of the financing tools offered by Seed Capital Bizkaia to support business initiatives with an innovative vocation that are in the early stages of their development.